You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

almonertinib

Showing 1 - 25 of 27
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Stage III Trial (Almonertinib)

Not yet recruiting
  • Lung Cancer Stage III
  • Almonertinib
  • (no location specified)
Aug 8, 2023

NSCLC Trial in Chendu (Almonertinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Almonertinib
  • Chendu, Sichuan, China
    West China Hospital，Sichuan University
Dec 14, 2022

Advanced NSCLC Trial in Jinan (almonertinib)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • almonertinib
  • Jinan, Shandong, China
    Degan Lu
Sep 12, 2023

Malignant Tumor of Lung, Poor Performance Status Trial in Guangzhou (Almonertinib)

Recruiting
  • Malignant Tumor of Lung
  • Poor Performance Status
  • Almonertinib
  • Guangzhou, Guangdong, China
    Zhou Chengzhi
Apr 12, 2023

Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

Recruiting
  • Brain Metastases
  • +2 more
  • brain radiotherapy
  • Almonertinib
  • Guangdong, Guangzhou, China
    Sun-Yat-Sen university
Mar 13, 2023

Relapsed or Advanced NSCLC Trial (Almonertinib combined with SHR-1701, Almonertinib)

Not yet recruiting
  • Relapsed or Advanced Non-small Cell Lung Cancer
  • Almonertinib combined with SHR-1701
  • Almonertinib
  • (no location specified)
Aug 16, 2022

NSCLC Trial in Changchun (Almonertinib, Placebo Almonertinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Almonertinib
  • Placebo Almonertinib
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Jun 13, 2022

NSCLC Metastatic Trial in Shanghai (Almonertinib, SBRT)

Recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Almonertinib
  • SBRT
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 23, 2023

NSCLC, Brain Metastases, Leptomeningeal Metastasis Trial in Zhengzhou (almonertinib, LM-first line treatment, LM-second line

Recruiting
  • NSCLC
  • +2 more
  • almonertinib
  • +2 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Aug 25, 2021

NSCLC, Stage III Trial in Wuhan (Almonertinib)

Recruiting
  • NSCLC, Stage III
  • Almonertinib
  • Wuhan, Hubei, China
    Tongji Hospital of Tongji Medical College of Huazhong University
Jul 4, 2021

NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation Trial in Nanchang (Almonertinib, Bevacizumab)

Not yet recruiting
  • NSCLC
  • +2 more
  • Nanchang, Jiangxi, China
    The Second Afiliated Hospital of Nanchang University
Jun 26, 2021

NSCLC Trial in Guangzhou (Almonertinib, chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun yat-sen Univerisity Cancer Center
Jun 30, 2021

Lung Cancer, EGFR Gene Mutation Trial (Almonertinib)

Not yet recruiting
  • Lung Cancer
  • EGFR Gene Mutation
  • Almonertinib
  • (no location specified)
May 6, 2021

NSCLC Trial (Almonertinib, Osimertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Apr 30, 2021

Lung Cancer Trial (Almonertinib)

Not yet recruiting
  • Lung Cancer
  • Almonertinib
  • (no location specified)
Apr 8, 2021

Safety of Almonertinib Trial in Guangzhou (Almonertinib)

Enrolling by invitation
  • Safety of Almonertinib
  • Almonertinib
  • Guangzhou, Guang Dong, China
    Sun Yat-sen University Cancer Center
Mar 4, 2021

NSCLC (NSCLC) Trial in Chongqing (Almonertinib, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Almonertinib
  • Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
May 31, 2021

Lung Cancer Trial in Hangzhou (Almonertinib)

Not yet recruiting
  • Lung Cancer
  • Almonertinib
  • Hangzhou, Zhejiang, China
    Cancer Hospital Affiliated to University of Chinese Academy of S
Mar 30, 2021

Non-small Cell Lung Carcinoma Trial in China (Almonertinib, Pemetrexed, Cisplatin)

Enrolling by invitation
  • Non-small Cell Lung Carcinoma
  • Almonertinib
  • +2 more
  • Beijing, Beijing, China
  • +33 more
Feb 8, 2022

Non Small Cell Lung Cancer, Stage III NSCLC, EGFR Activating Mutation Trial in Hangzhou (Almonertinib)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Almonertinib
  • Hangzhou, Zhejiang, China
    Hangzhou Cancer hospital
Jan 8, 2021

Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation Trial in Shanghai (Almonertinib, Pemetrexed, Carboplatin)

Unknown status
  • Lung Cancer, Non-small Cell
  • +2 more
  • Almonertinib
  • +2 more
  • Shanghai, Shanghai, China
    Cancer hospital Fudan University
Oct 15, 2020

EGFR Positive NSCLC, Brain Metastases Trial in Hangzhou (Almonertinib)

Not yet recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Brain Metastases
  • Almonertinib
  • Hangzhou, Zhejiang, China
    Hangzhou Cancer Hospital
Nov 19, 2020

Non Small Cell Lung Cancer Trial in Tianjin (Almonertinib)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Almonertinib
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 9, 2020

Non Small Cell Lung Cancer Trial in Beijing, Tianjin (Almonertinib, Almonertinib plus carboplatin and pemetrexed)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Almonertinib
  • Almonertinib plus carboplatin and pemetrexed
  • Beijing, China
  • +4 more
Aug 2, 2020

Non Small Cell Lung Cancer Trial in Beijing, Tianjin (Almonertinib, Almonertinib plus carboplatin and pemetrexed)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Almonertinib
  • Almonertinib plus carboplatin and pemetrexed
  • Beijing, Beijing, China
  • +5 more
Aug 4, 2020